Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Effects of Transcranial Direct Current Stimulation (tDCS) in the Management of Suicidal Ideation

NCT06009523 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-10-26
Last updated
2026-10-23

Condition(s) studied

Depression and Suicide

Investigational drug(s) / intervention(s)

Transcranial direct current stimulation

Transcranial direct current stimulation: 1 stimulation per day during 15 days.

Study summary

The main objective of this study is to demonstrate that 15 transcranial direct current stimulation (tDCS) sessions of 30 minutes at 2 mA intensity are effective to reduce suicidal ideation

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age over 18 years * Written informed consent * Diagnosis of recurrent or isolated depressive episode according to DSM IV criteria (A.P.A. 1994). * Stable antidepressant treatment for 3 weeks * MADRS score ≥ 20 * SSI score \> 3 * Subject affiliated to a health insurance system * Woman with effective contraception and agreeing to maintain it throughout the study period. Exclusion Criteria: * Depression with psychotic features Axis I (DSM IV) co-morbid diagnosis of schizophrenia, alcohol and/or other substance dependence (or abuse) (lifetime) * Patient who has already undergone an electroconvulsive therapy course for the current episode and does not respond to this treatment * Patient deprived of liberty * Patient with high suicide risk (item 10 MADRS \> 4) in the absence of hospitalization * Contraindication to tDCS: intracerebral metallic implant (with the exception of dental implants), cardiac pacemaker, active or non-implanted devices in the region of the head, acute eczema in the planned stimulation area * Pregnant, parturient or breastfeeding woman * Simultaneous participation in another interventional research

Primary outcome measure(s)

  • Change from Baseline in suicidal ideation on the Scale for Suicide Ideation (SSI) at "Day 19" — Baseline and "Day 19"
    The main judgment criterion is the evolution of suicidal ideation which is evaluated by the Beck Scale for Suicide Ideation (SSI) between Baseline and "Day 19"

Trial sites (2)

FacilityCityRegionStatus
Centre Hospitalier Nord-Deux-Sèvres Faye-l'Abbesse France Recruiting
Centre Hospitalier Henri Laborit Poitiers France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06009523 on ClinicalTrials.gov ↗ ← All trials in France